Molecular determinants of anti-RBC alloantibody evanescence
抗红细胞同种抗体消失的分子决定因素
基本信息
- 批准号:10687424
- 负责人:
- 金额:$ 79.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-13 至 2023-10-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAllogenicAlloimmunizationAntibodiesAntibody AffinityAntibody FormationAntibody ResponseAntigen PresentationAntigen-Presenting CellsAntigensApoptoticAutomobile DrivingB cell differentiationB-LymphocytesBiological Response ModifiersBloodBlood BanksCD4 Positive T LymphocytesCell Differentiation processCellsCessation of lifeChronicChronic CareClinicalComplicationCoupledDataDendritic CellsDendritic cell activationDependenceDetectionDevelopmentDiagnosticDropsErythrocyte TransfusionErythrocytesEventFutureGenerationsHelper-Inducer T-LymphocyteImmuneImmune responseImmunoglobulin Somatic HypermutationInflammatoryInjuryInnate Immune ResponseInnate Immune SystemInterleukin-10Interleukin-4IsoantibodiesLeadLifeLipidsMalariaModelingMolecularMolecular TargetMorbidity - disease ratePatientsPhenotypePlasma CellsPlasmablastPlatelet Activating FactorProcessProductionPublishingReactionRiskSerineSickle Cell AnemiaSignal TransductionStructure of germinal center of lymph nodeT-LymphocyteTNFSF4 geneTestingTherapeuticTherapeutic InterventionTimeTransfusionVaccinationVirus Diseasesclinical developmentdifferential expressionfallshazardhigh riskmalaria infectionmortalitymouse modelnovelnovel therapeutic interventionpatient responseresponsetherapeutically effective
项目摘要
Summary. For patients who require chronic transfusion, the generation of antibodies to red blood cell (RBC)
antigens can be a major clinical problem. Anti-RBC antibodies often make finding compatible blood difficult
for these patients, which is particularly unfortunate since these RBC transfusions are often lifesaving. A major
complication arises when these anti-RBC alloantibodies disappear before detection in the blood bank, a
process referred to as evanescence. Patients whose antibodies have disappeared can unknowingly receive
a second transfusion of incompatible blood. This incompatible transfusion can induce a life-threatening event
called delayed hemolytic transfusion reaction. Anti-RBC evanescence therefore directly leads to delayed
hemolytic transfusion reactions, which are a major cause of injury and death in chronically transfused patients.
This is a particularly serious problem for patients with sickle cell disease, who often require frequent
transfusions and have high rates of evanescent antibodies. Despite its clinical importance, the molecular
factors that lead to anti-RBC alloantibody evanescence are completely unknown. Accordingly, there are no
effective therapeutic interventions available to alloimmunized patients other than antigen avoidance. We have
recently made the novel finding that the HOD mouse model of red blood cell (RBC) alloimmunization
recapitulates many of the key clinical features seen in chronically transfused patients. Specifically, we have
shown that HOD RBC transfusion leads to the preferential generation of low-affinity, rapidly evanescent anti-
RBC alloantibodies at the expense of high-affinity, persistent antibodies. Herein we propose to use this mouse
model to investigate why RBC transfusion leads to rapidly evanescent antibodies rather than long-lived ones.
Our central hypothesis is that RBC presentation of antigens directly alters the innate immune responses of
recipients, driving the differentiation of CD4+ T cells into helper cells which are unable to sustain long-lived
interactions with B cells. We hypothesize that though these T cells can drive extrafollicular antibody responses
that produce low-affinity, short-lived antibodies, they are blocked in their ability to drive germinal center
responses that allow for somatic hypermutation, antibody affinity maturation, and long-lived antibody
producing plasma cells. By better understanding how the fundamental cellular and molecular immune
regulators of anti-RBC alloantibodies are regulated over time, we hope to discover novel molecular targets
that can serve as potential future therapeutics for those patients who are at high risk from the complications
of RBC alloimmunization.
摘要对于需要长期输血的患者,红细胞(RBC)抗体的产生
抗原可能是主要的临床问题。抗红细胞抗体通常使寻找相容血液变得困难
对于这些病人来说,这是特别不幸的,因为这些红细胞输注通常可以挽救生命。一个主要
当这些抗RBC同种抗体在血库中检测到之前消失时,
这个过程被称为消逝。抗体消失的患者会在不知不觉中
第二次输入不相容的血液这种不相容的输血会导致危及生命的事件
称为迟发性溶血性输血反应。因此,抗RBC消失直接导致延迟的
溶血性输血反应是慢性输血患者受伤和死亡的主要原因。
对于镰状细胞病患者来说,这是一个特别严重的问题,
输血和有很高的渐逝性抗体的比率。尽管它的临床重要性,分子
导致抗RBC同种抗体消失的因素是完全未知的。因此,没有
有效的治疗干预措施可用于同种免疫患者,而不是抗原回避。我们有
最近有了新的发现,红细胞同种免疫的HOD小鼠模型
概括了在慢性输血患者中观察到的许多关键临床特征。具体来说,我们有
表明HOD RBC输注导致低亲和力、快速消失的抗-
RBC同种抗体以高亲和力持久抗体为代价。在此,我们建议使用此鼠标
研究为什么红细胞输注会导致快速消失的抗体而不是长寿命的抗体。
我们的中心假设是,红细胞抗原呈递直接改变了先天性免疫反应,
受体,驱动CD 4 + T细胞分化为辅助细胞,无法维持长寿命
与B细胞的相互作用。我们假设,虽然这些T细胞可以驱动滤泡外抗体反应,
产生低亲和力、短寿命的抗体,它们驱动生发中心的能力被阻断,
允许体细胞超突变、抗体亲和力成熟和长寿命抗体的应答
产生浆细胞。通过更好地理解基本的细胞和分子免疫
抗红细胞同种抗体的调节因子随时间而调节,我们希望发现新的分子靶点
这可以作为潜在的未来疗法,用于那些并发症风险高的患者,
RBC同种异体免疫
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHANCE MARION JOHN LUCKEY其他文献
CHANCE MARION JOHN LUCKEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHANCE MARION JOHN LUCKEY', 18)}}的其他基金
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 2
红细胞输注同种免疫的基本和转化机制。
- 批准号:
10711669 - 财政年份:2023
- 资助金额:
$ 79.83万 - 项目类别:
Cellular and Molecular Determinants of RBC Alloimmunization Responder Status
红细胞同种免疫应答状态的细胞和分子决定因素
- 批准号:
10192795 - 财政年份:2017
- 资助金额:
$ 79.83万 - 项目类别:
Cyokine control of red blood cell alloimmunization
红细胞同种免疫的细胞因子控制
- 批准号:
9214994 - 财政年份:2016
- 资助金额:
$ 79.83万 - 项目类别:
Transcriptional Control of Memory Responses to Red Blood Cell Alloimmunization
红细胞同种免疫记忆反应的转录控制
- 批准号:
9017157 - 财政年份:2014
- 资助金额:
$ 79.83万 - 项目类别:
Transcriptional Control of Memory Responses to Red Blood Cell Alloimmunization
红细胞同种免疫记忆反应的转录控制
- 批准号:
8567036 - 财政年份:2013
- 资助金额:
$ 79.83万 - 项目类别:
Transcriptional Control of Memory Responses to Red Blood Cell Alloimmunization
红细胞同种免疫记忆反应的转录控制
- 批准号:
8703785 - 财政年份:2013
- 资助金额:
$ 79.83万 - 项目类别:
Cytokine control of Red Blood Cell Alloimmunization
红细胞同种免疫的细胞因子控制
- 批准号:
8228956 - 财政年份:2012
- 资助金额:
$ 79.83万 - 项目类别:
Cytokine control of Red Blood Cell Alloimmunization
红细胞同种免疫的细胞因子控制
- 批准号:
8424288 - 财政年份:2012
- 资助金额:
$ 79.83万 - 项目类别:
Pou6f1 transcriptional control of memory CD8+ T cells
Pou6f1 记忆 CD8 T 细胞的转录控制
- 批准号:
8164939 - 财政年份:2011
- 资助金额:
$ 79.83万 - 项目类别:
Pou6f1 transcriptional control of memory CD8+ T cells
Pou6f1 记忆 CD8 T 细胞的转录控制
- 批准号:
8264746 - 财政年份:2011
- 资助金额:
$ 79.83万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 79.83万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 79.83万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 79.83万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)